688373 Stock Overview
A biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Shanghai MicuRx Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.00 |
| 52 Week High | CN¥6.77 |
| 52 Week Low | CN¥3.23 |
| Beta | 0.65 |
| 1 Month Change | -4.21% |
| 3 Month Change | 24.07% |
| 1 Year Change | -21.14% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.04% |
Recent News & Updates
Shanghai MicuRx Pharmaceutical Co., Ltd.'s (SHSE:688373) Shares Climb 30% But Its Business Is Yet to Catch Up
Dec 02
There's Reason For Concern Over Shanghai MicuRx Pharmaceutical Co., Ltd.'s (SHSE:688373) Massive 30% Price Jump
Dec 02Recent updates
Shanghai MicuRx Pharmaceutical Co., Ltd.'s (SHSE:688373) Shares Climb 30% But Its Business Is Yet to Catch Up
Dec 02There's Reason For Concern Over Shanghai MicuRx Pharmaceutical Co., Ltd.'s (SHSE:688373) Massive 30% Price Jump
Dec 02Shanghai MicuRx Pharmaceutical Co., Ltd.'s (SHSE:688373) 26% Share Price Surge Not Quite Adding Up
Apr 07Shareholder Returns
| 688373 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -10.6% | -0.7% | 0.4% |
| 1Y | -21.1% | -18.4% | 12.3% |
Return vs Industry: 688373 underperformed the CN Biotechs industry which returned -18.4% over the past year.
Return vs Market: 688373 underperformed the CN Market which returned 12.3% over the past year.
Price Volatility
| 688373 volatility | |
|---|---|
| 688373 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688373 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688373's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 188 | Yuan Zhengyu | www.micurxchina.com |
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd.
Shanghai MicuRx Pharmaceutical Co., Ltd. Fundamentals Summary
| 688373 fundamental statistics | |
|---|---|
| Market cap | CN¥3.35b |
| Earnings (TTM) | -CN¥467.96m |
| Revenue (TTM) | CN¥120.07m |
27.3x
P/S Ratio-7.0x
P/E RatioIs 688373 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688373 income statement (TTM) | |
|---|---|
| Revenue | CN¥120.07m |
| Cost of Revenue | CN¥21.53m |
| Gross Profit | CN¥98.54m |
| Other Expenses | CN¥566.50m |
| Earnings | -CN¥467.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 82.07% |
| Net Profit Margin | -389.75% |
| Debt/Equity Ratio | 40.4% |
How did 688373 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 15:57 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai MicuRx Pharmaceutical Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mingrui Wang | Everbright Securities Co. Ltd. |